To Get Full Access :
Loargys (pegzilarginase-nbln) is indicated for the treatment of Arginase 1 Deficiency (ARG1-D), also known as hyperargininemia, in adult and pediatric patients 2 years of age and older, a rare urea cycle disorder characterized by elevated plasma arginine levels and progressive neurological impairment.
Loargys functions as an enzyme replacement therapy, reducing toxic arginine accumulation and helping to manage the metabolic and neurological complications associated with the disease.
Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets
For full access Sign-up / Sign-in using below Methods:
By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.
